Satellos Bioscience (MSLE) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Satellos Bioscience (MSLE) is Moderate Underperform.

The composite score behind that read is -0.27, weighing +0.21 of bullish evidence against -0.37 bearish.

Satellos Bioscience last closed at $7.54, -6.34% on the session.

Against the IVW growth benchmark the position is -6.95% over the forecast window.

The read is built from 12 underlying insights — 3 bullish and 9 bearish.

Agreement across those insights is 75%.

15 graded predictions for MSLE so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Satellos Bioscience in the 14th percentile on return on equity, where 100 is best.

Satellos Bioscience is classified under Health Care / Biotechnology, with a market capitalisation of $170.79M.

StockMap tracks Satellos Bioscience as the 247th largest of the 365 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 190 Moderate Underperform, 164 Neutral and 11 Strong Underperform.

On that composite Satellos Bioscience ranks 248th of 365 in the group, against a group median of -0.21.